Edwards Lifesciences Corp (NYSE:EW) Shares Bought by OppenheimerFunds Inc.

OppenheimerFunds Inc. boosted its holdings in Edwards Lifesciences Corp (NYSE:EW) by 5.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 161,270 shares of the medical research company’s stock after acquiring an additional 8,684 shares during the period. OppenheimerFunds Inc. owned 0.08% of Edwards Lifesciences worth $23,476,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in EW. FMR LLC raised its position in Edwards Lifesciences by 32.9% in the second quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock valued at $977,456,000 after purchasing an additional 1,663,511 shares during the period. First Trust Advisors LP raised its position in Edwards Lifesciences by 633.6% in the second quarter. First Trust Advisors LP now owns 364,884 shares of the medical research company’s stock valued at $53,116,000 after purchasing an additional 315,144 shares during the period. Jennison Associates LLC raised its position in Edwards Lifesciences by 46.9% in the second quarter. Jennison Associates LLC now owns 845,649 shares of the medical research company’s stock valued at $123,101,000 after purchasing an additional 270,048 shares during the period. AKO Capital LLP purchased a new stake in Edwards Lifesciences in the second quarter valued at approximately $35,422,000. Finally, BlackRock Inc. raised its position in Edwards Lifesciences by 1.6% in the first quarter. BlackRock Inc. now owns 15,653,522 shares of the medical research company’s stock valued at $2,183,978,000 after purchasing an additional 242,785 shares during the period. Hedge funds and other institutional investors own 82.10% of the company’s stock.

In other news, VP Donald E. Bobo, Jr. sold 5,500 shares of the stock in a transaction dated Wednesday, July 11th. The shares were sold at an average price of $145.57, for a total transaction of $800,635.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Larry L. Wood sold 6,300 shares of the stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $148.02, for a total transaction of $932,526.00. Following the sale, the vice president now owns 121,950 shares of the company’s stock, valued at approximately $18,051,039. The disclosure for this sale can be found here. Insiders sold 155,011 shares of company stock valued at $22,147,646 in the last 90 days. 1.84% of the stock is currently owned by insiders.

A number of analysts have recently weighed in on EW shares. Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research report on Saturday, July 14th. ValuEngine raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Tuesday, June 12th. Guggenheim reaffirmed a “buy” rating and set a $170.00 price objective on shares of Edwards Lifesciences in a research report on Friday, July 27th. Jefferies Financial Group reaffirmed a “buy” rating and set a $168.00 price objective on shares of Edwards Lifesciences in a research report on Friday, July 27th. Finally, SunTrust Banks cut their price objective on Edwards Lifesciences to $170.00 and set a “buy” rating on the stock in a research report on Friday, August 10th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $154.95.

NYSE:EW opened at $147.15 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.47 and a current ratio of 1.86. Edwards Lifesciences Corp has a 12 month low of $100.20 and a 12 month high of $175.00. The firm has a market capitalization of $36.45 billion, a P/E ratio of 39.76, a price-to-earnings-growth ratio of 2.41 and a beta of 0.56.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.11. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The company had revenue of $972.00 million during the quarter, compared to the consensus estimate of $968.32 million. During the same quarter in the prior year, the firm posted $1.08 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 10.0% on a year-over-year basis. Analysts predict that Edwards Lifesciences Corp will post 4.67 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Featured Story: The Discount Rate – What You Need to Know

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply